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Abstract
Farnesoid X receptor (FXR) is a ligand-activated nuclear receptor and serves as a key regulator to
maintain health of the liver and intestine. Bile acids are endogenous ligands of FXR, and there are
increasing efforts to identify FXR modulators to serve as biological probes and/or pharmaceutical
agents. Natural FXR ligands isolated from plants may serve as models to synthesize novel FXR
modulators. In this study, we demonstrated that epigallocatechin-3-gallate (EGCG), a major tea
catechin, specifically and dose-dependently activates FXR. In addition, EGCG induced FXR target
gene expression in vitro. Surprisingly, in a co-activator (SRC2) recruitment assay, we found that
EGCG does not recruit SRC2 to FXR, but it dose-dependently inhibits recruitment of SRC2 to
FXR (IC50, 1 μM) by GW6064, which is a potent FXR synthetic ligand. In addition, EGCG
suppressed FXR target gene expression induced by either GW4064 or chenodeoxycholic acid in
vitro. Furthermore, wild-type and FXR knockout mice treated with an acute dose of EGCG had
induced mRNA expression in a subset of FXR target genes in the intestine but not in the liver. In
conclusion, EGCG is a unique modulator of FXR in the intestine and may serve as an important
model for future development of FXR modulators.
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FXR (farnesoid X receptor, NR1H4) is a ligand-activated transcription factor and a member
of the nuclear receptor superfamily. Bile acids are FXR’s endogenous ligands. FXR
regulates the biosynthesis and enterohepatic circulation of bile acids in addition to its
regulation of triglyceride, cholesterol and glucose metabolism (Sinal et al., 2000; Cariou et
al., 2005; Rizzo et al., 2005; Ma et al., 2006; Zhang et al., 2006). Recent evidence shows
that FXR is also critical in maintaining innate immune responses in intestine (Vavassori et
al., 2009). In addition, FXR deficiency in mice results in increased cholestasis, non-
alcoholic fatty liver diseases, hepatocellular carcinoma and colon cancer (Gadaleta et al.,
2010). This evidence suggests that FXR and FXR-mediated signaling pathways may be
promising novel drug targets for the treatment of common metabolic diseases. However, use
of synthetic FXR ligands in the clinic has not yet been approved.
The goal of the current study is to screen for FXR modulators in tea plant. Tea is a
traditional medicinal plant and is also the most widely consumed beverage in the world,
second only to water. The most commonly consumed teas are black, green, and oolong.
These teas are all derived from the plant Camellia sinensis, which is a member of the
Theaceae family. Epidemiologic and animal studies suggest that drinking green tea offers
protection against cardiovascular diseases and a variety of cancers (oral cavity, esophagus,
stomach, liver, small and large intestine, and mammary gland) (Setiawan et al., 2001; Zhang
et al., 2002; Wu et al., 2003; Jian et al., 2004; Cabrera et al., 2006). Catechins are
polyphenolic compounds and are one class of major chemicals found in tea. Examples of tea
catechins include (−)-epigallocatechins-3-gallate (EGCG), (−)-epigallocatechin (EGC), (−)-
epicatechin-3-gallate (ECG), and (−)-epicatechin (EC) (Figure 1). EGCG is the major
constituent and the most biologically active catechin of green tea. Numerous studies report
that EGCG can lower oxidative stress, atherosclerosis, inflammation, and cholesterol (Dona
et al., 2003; Frei and Higdon, 2003; Raederstorff et al., 2003; Chyu et al., 2004). However,
no effect of tea compounds on FXR activity has been reported. Therefore, we aimed to




Thirty-four commercially available samples of green tea (5g) were extracted with 10 mL of
H2O (70°C, for 10 min) to simulate conditions of regular infusion. The resulting aqueous
extracts were concentrated in vacuo and dried overnight at 30°C in a vacuum oven. All plant
samples were prepared at the Department of Medicinal Chemistry, University of Kansas
Lawrence. GW4064 was synthesized by the Department of Medicinal Chemistry, University
of Kansas. Chenodeoxycholic acid (CDCA), ECG, EGC, and EGCG were purchased from
Sigma-Aldrich (St. Louis, MO). All compounds and catechins were dissolved in DMSO for
in vitro studies. For the in vivo study, EGCG was dissolved in 0.9% saline and stored at
−20°C.
Cell culture
Human hepatocellular carcinoma cell lines HepG2 and Hep3B were purchased from
American Type Culture Collection (Manassas, VA). The Huh7 cell line was purchased from
RIKEN BioResource Center (Tsukuba, Japan). All cells were cultured in high-glucose
DMEM supplemented with 1% penicillin/streptomycin, 1% L-glutamine, and 10% fetal
bovine serum (Omega Scientific, Tarzana, CA). All cells were maintained in a 5% CO2
humidified atmosphere at 37°C.
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Transient transfection and luciferase reporter gene assays
The generation of the pGL4-SHP-TK promoter luciferase reporter was described in detail
previously (Li et al., 2010). Briefly, the downstream regulatory region of the Nr0b2 gene,
from +3639 to +4516 relative to the transcription start site, was amplified from mouse
genomic DNA by PCR using pairs of primers containing XhoI and BglII restriction enzyme
sites, respectively. The PCR product was subcloned upstream of the luciferase gene into the
firefly luciferase pGL4-TK vector (Promega, Madison, WI) and was named pGL4-SHP-TK
reporter vector. The sequence of the construct was confirmed by DNA sequencing. HepG2
cells were seeded in a 96-well plate and grown to 90% confluency prior to transient
transfection with plasmids consisting of PGL4-SHP-TK reporter gene, pCMV-ICIS human
FXR (Open Biosystems, Huntsville, AL), pSG5 human RXRα (Stratagene, La Jolla, CA),
and pCMV-renilla luciferase vector (Promega, Madison, WI). Transient transfection was
carried out according to the manufacturer’s instructions using TurboFect in vitro
Transfection Reagent (Fermentas, Glen Burnie, MD). To screen for plant compounds that
activate FXR, cells were treated with 0.1% DMSO (negative control), 1 μM GW4064
(positive control), or various testing compounds at indicated concentrations five hours after
transfection. To test the effects of EGCG on GW4064 or CDCA activation of FXR, cells
were treated five hours after transfection with 500 nM GW4064 or 100 μM CDCA in the
absence or presence of increasing concentrations of EGCG (0 to 100 μM) or 0.1% DMSO as
a negative control. Thirty-six hours after treatment, firefly luciferase and renilla luciferase
activities were quantified using the Dual-Glo Luciferase Kit (Promega, Madison, WI) in a
Synergy-II HT plate reader (Bio-Tek Instruments, Inc., Winooski, VT). The firefly
luciferase activity value was normalized as a ratio to that of renilla luciferase and expressed
as fold over the pGL4-SHP-TK vector control. For plant compound screening, the data were
presented as an average of three assays. For the dose response of ECG, EGC, and EGCG,
the data were presented as an average of six wells. For the activation effects of EGCG
combined with GW4064 or CDCA on FXR, the data were also presented as an average of
six wells. All experiments were repeated at least twice.
FXR-mediated co-activator recruitment assay
Time-resolved fluorescence resonance transfer (TR-FRET) hFXR coactivator recruitment
assays were performed according to the manufacturer’s instructions (Invitrogen) with minor
modifications. Briefly, the assays were performed in 384-well low volume (20 μl per well)
solid black plates with 5 nM GST-FXR ligand-binding domain (LBD), 500 nM fluorescent-
SRC2-2, 5 nM terbium-labeled anti-GST antibody and a test compound at various
concentrations. A potent FXR agonist, GW4064, and DMSO were included in assays as
positive and negative controls, respectively. The DMSO concentration was 1% in all assay
wells.
In the reaction mixture containing GW4064, GST-FXR forms a complex with the terbium-
labeled anti-GST antibody and co-activator peptide, fluorescent-SRC2-2. Excitation of
terbium using a 340-nm excitation filter results in an energy transfer from terbium to the
fluorophore of the labeled co-activator peptide. This energy transfer is detected by an
increase in fluorescence emission of the labeled co-activator peptide at 520 nm and a
decrease in fluorescence emission of terbium at 495 nm. The FRET ratio was calculated by
dividing the emission signal at 520 nm by the emission signal at 495 nm. In the absence of a
FXR agonist or addition of a FXR antagonist, GST-FXR fails to recruit the co-activator
fluorescent-SRC2-2 causing a decrease of the FRET ratio. The reactions were incubated at
25 °C for 1 hour before measuring the fluorescent emission of each well at 495 and 520 nm
using a 340-nm excitation filter, 100-μs delay time, and 200-μs integration time on a
PHERAStar plate reader (BMG Labtech, Durham, NC). The FRET ratios were normalized
so 100% activation and 0% activation represents the activity of GW4064 at 100 μM and 0
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μM, respectively. The curve-fitting software GraphPad Prism 4.0 was used to generate the
curves and determine the EC50 or IC50 values. The potent FXR agonist GW4064 has an
EC50 of 8.01 nM in this assay.
Animals and treatments
Wild-type (WT) and FXR-knockout (KO) male mice in C57BL/6J genetic background were
used in this study (8–10 weeks old, n = 5–6 per group). All mice were housed in pathogen-
free animal facilities under a standard 12-h light/dark cycle with access to regular rodent
chow and autoclaved tap water ad libitum. The study was carried out in strict accordance
with the recommendations in the Guide for the Care and Use of Laboratory Animals of the
National Institute of Health. All protocols and procedures were approved by the University
of Kansas Medical Center Animal Care and Use Committee. The protocol number approved
for this study was 2010-1947. EGCG was dissolved in 0.9% saline at 10 mg/ml or 2.5 mg/ml
and was administered twice to mice either orally (P.O.) at 100 mg/kg or intraperitoneally
(I.P.) at 25 mg/kg. The first dose was administered at 7 pm followed by a second dose at 7
am the next day. The control groups were treated with 0.9% saline. Two hours after the
second treatment, blood was collected, and livers, small intestines, and kidneys were
removed. Ileums were flushed with 1X Phosphate Buffered Saline (PBS) buffer. All tissues
were snap-frozen in liquid nitrogen and stored at −80 °C before further analysis.
Determination of serum alanine aminotransferase (ALT) activity
Blood samples were collected in microtainer serum separator tubes (BD Biosciences, San
Jose, CA) and allowed to clot at room temperature for 30 min before centrifugation at 8,000
× g and 4 °C for 15 min for serum collection. Serum was stored at −80 °C until analysis.
The kit for analyzing serum ALT activity was obtained from Pointe Scientific (Canton, MI).
All measurements were performed according to the manufacturer’s instructions.
RNA isolation and quantitative real-time PCR (Q-PCR)
For in vitro study, HepG2, Hep3B, and Huh7 cells were grown to 80% confluency before
treatment. To test the effect of ECG, EGC or EGCG on the expression of FXR target genes,
HepG2 cells were treated with 10 μM of each catechin for 24 hours. To test a dose response
effect of EGCG on FXR target gene expression, HepG2, Hep3B, and Huh7 cells were
treated with increasing concentrations of EGCG for 24 hours. To test the effect of EGCG on
the expression of FXR target genes in the presence of GW4064 or CDCA, cells were treated
with EGCG or EGCG combined with GW4064 or CDCA for 24 hours. Total RNA was
extracted from treated cells using Trizol reagent (Invitrogen, Carlsbad, CA) according to the
manufacturer’s instructions. The concentration of total RNA was determined by
spectrophotometry, and RNA integrity was confirmed by MOPS gel electrophoresis. The
mRNA expression levels of FXR and its target genes small heterodimer partner (SHP),
organic solute transporter α (OSTα), organic solute transporter β (OSTβ), and bile salt efflux
pump (BSEP) were quantified by Q-PCR using SYBR green chemistry, and results were
normalized to GAPDH RNA levels. For in vivo studies, frozen livers, ileums, and kidneys
collected from mice treated with vehicle or EGCG were used to isolate total RNA. The
mRNA expression levels of Fxr and its target genes Shp, Cyp7a1 and Bsep in liver and
ileum bile acid binding protein (Ibabp) and fibroblast growth factor (Fgf15) in ileum were
quantified by Q-PCR using SYBR green chemistry. Results were normalized to Gapdh RNA
levels. The primer sequences used in Q-PCR are presented in supplemental data (Table S1).
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All data were presented as mean ± SD. All data were analyzed by one-way analysis of
variance followed by the Student-Newman-Keuls test. P < 0.05 is considered statistically
significant.
Results
Screen of tea preparations for activation of FXR by luciferase assay
Crude extracts from various tea aqueous extracts were used to screen for FXR modulators
by luciferase assay. Most of the crude tea extracts activated FXR, but FXR activation was
weak (Figure S1). The major active components in tea are polyphenols with EGCG as the
major component followed by EGC, ECG and EC. However, great variations of polyphenols
are observed among different types and sources of teas. Therefore, we tested two chemical
preparations, A007 (ECG + EGC) and A009 (EGC + EGCG), to determine if a combination
of pure tea compounds activates FXR. These Mixtures contained an equal molar
concentration of each tea compound. Compared to vehicle control, A007 and A009 both
activated FXR 2.6 to 4.8 fold at concentrations of 10 μM and 100 μM, respectively (Figure
2).
Dose response of EGCG, ECG and EGC in FXR activation in luciferase assay
A dose-response of EGCG, EGC, and ECG in activation of FXR was determined by
luciferase assay using increasing concentrations of EGCG, EGC or ECG (0.01, 0.1, 1, 10
and 100 μM). All three chemicals dose-dependently increased the luciferase activity with
EGCG > EGC = ECG. The maximum response reached a plateau at 10 μM with an
approximate 7 to 9-fold increase in luciferase activity (Figure 3A). The EC50 of EGCG for
FXR activation was 2.99 μM (Figures 3A, B). EGCG-mediated activation of FXR appears to
be specific because other nuclear receptors, including pregnane X receptor (PXR),
constitutive androstane receptor (CAR), vitamin D receptor (VDR), retinoic acid receptor
alpha (RXRα) and retinoic acid receptor beta (RXRβ), were not activated by EGCG (Figure
S2).
Induction of FXR target genes in HepG2 cells by tea catechins
We then determined whether EGCG, EGC and ECG induce gene expression of the classical
FXR target genes SHP, OSTα and BSEP in HepG2 cells (Figure S3). SHP is an orphan
nuclear receptor, OSTα transports bile acids as a heterodimer with OSTβ, and BSEP is a bile
acid efflux transporter. The expression of these genes is induced by FXR activation via
direct binding of FXR to their gene regulatory regions (Cui et al., 2003; Landrier et al.,
2006). Similar to the positive control, GW4064, all three catechins increased the mRNA
levels of SHP and BSEP, but not OSTα, at 10 μM.
EGCG didn’t recruit coactivator to FXR, but suppressed GW4064-mediated recruitment of
coactivator and FXR transactivation
To determine whether EGCG activates FXR via coactivator recruitment, a coactivator
recruitment assay was performed. The result revealed that although EGCG itself did not
recruit the coactivator SRC2 to FXR (Figures 4A), it strongly inhibited the GW4064-
mediated recruitment of SRC2 to FXR with an IC50 of 1 μM (Figures 4A). Guggulsterone is
a known FXR partial agonist that has also been reported to function as an antagonist in
coactivator recruitment (Cui et al., 2003). Guggulsterone inhibited 50% of GW4064-
mediated coactivator recruitment at 86 μM, which was significantly less potent than EGCG
(Figure S4). However, the ability of guggulsterone alone to induce coactivator recruitment
was higher than that of EGCG alone (Figures 4A and Figure S4), suggesting that EGCG and
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guggulsterone might represent two unique classes of FXR modulators. Luciferase assays
were then used to further determine if EGCG inhibits other agonists’ activation of FXR.
HepG2 cells were treated with the known FXR agonists GW4064 (500 nM) or CDCA (100
μM) in the absence or presence of increasing concentrations of EGCG. Although treatment
with EGCG alone dose-dependently increased FXR activity, it partially inhibited activation
of FXR by GW4064 or CDCA in a dose dependent manner (Figure 4B). FXR activation by
GW4064 or CDCA was reduced 35% and 48% by 100 μM EGCG, respectively. According
to these data, EGCG behaves as a unique FXR modulator which can suppress the activity of
other FXR agonists.
To further confirm that EGCG is an activator of FXR with antagonistic effects on other FXR
agonists, the effects of EGCG on FXR target gene expression in the presence of GW4064 or
CDCA were determined by measuring mRNA levels in HepG2, Hep3B, and Huh7 cells.
GW4064 and CDCA strongly induced mRNA expression of FXR target genes in all three
cell lines. When cells were co-treated with increasing concentrations of EGCG and GW4064
or CDCA, mRNA levels of FXR target genes, OSTβ and BSEP, were dose-dependently
decreased in HepG2 cells compared to treatment with GW4064 or CDCA alone (Figure 5).
In addition, OSTβ was dose-dependently decreased in Hep3B and Huh7 cells (Figure S5,
S6). Furthermore, FXR and its target genes SHP, OSTα, OSTβ and BSEP were all decreased
when co-treated with 100 μM of EGCG and GW4064 or CDCA in HepG2 cells (Figure 5).
Similar results were also found in Hep3B and Huh7 cells (Figure S5, S6).
Activation of FXR by EGCG in vivo
FXR activation in liver and small intestine by acute EGCG treatment was evaluated in WT
and FXR-KO mice. Higher concentrations of EGCG are known to be hepatotoxic (Goodin
and Rosengren, 2003; Lambert et al., 2010), so we used lower concentrations of EGCG in
this study to avoid liver toxicity. There was no change in the serum activity of ALT with
EGCG treatment, which confirmed that there was no obvious liver toxicity associated with
the EGCG dose selected (Figure 6).
EGCG treatment administered by I.P. or P.O. did not alter mRNA expression levels of FXR
target genes Shp, Bsep, or Cyp7a1 in the liver (Figure S7). In contrast, I.P. administration of
EGCG increased Shp mRNA levels by 2-fold, and P.O. administration of EGCG induced
mRNA levels of Shp by 12-fold and Fgf15 by 2-fold in the small intestine of WT mice, but
not of FXR-KO mice (Figure 7). Unlike treatment with the synthetic FXR agonist GW4064,
which strongly induces expression of all FXR target genes in intestine (Kim et al., 2007a),
EGCG selectively induced expression of Shp and Fgf15, but not Ibabp (Figure 7). In the
kidney, neither I.P. nor P.O. administration of EGCG altered mRNA expression levels of
Fxr or its target gene Shp (Figure S8).
Discussion
The current study identified unique FXR modulators from tea. FXR was activated by tea
catechins EGCG, EGC and ECG in a dose-dependent manner as shown by luciferase assay.
Activation of FXR by tea catechins induced FXR target gene expression in vitro. However,
EGCG by itself did not recruit coactivators to FXR; it instead inhibited FXR agonist-
mediated recruitment of coactivators and transactivation of FXR. Notably, activation of
FXR by EGCG in vivo appears to be tissue-specific because only intestinal, but not hepatic,
FXR was activated by EGCG. Furthermore, FXR was activated by EGCG in the small
intestine, but only a subset of FXR target genes was induced.
Our results identified that catechins are natural FXR modulators. There are currently few
reports on FXR activation by natural plant compounds. The only compound extracted from
Li et al. Page 6













plants reported to activate FXR is cafestol, a diterpene present in unfiltered coffee brews
(Ricketts et al., 2007). Cafestol is not specific for FXR activation because it also activates
PXR. In this study, we determined that EGCG activates FXR without activating other
nuclear receptors including RXRα, RXRβ, CAR, and VDR.
In comparison with FXR agonists GW4064 and CDCA, the potency of EGCG in activation
of FXR is modest. The EC50 of two FXR full agonists, CDCA and GW4064, in activating
human FXR are 10 μM and 15 nM, respectively. The EC50 of EGCG to activate human
FXR in luciferase assay is 2.99 μM. EGCG is able to activate FXR in vitro at a range of 1 to
10 μM. It is reported that in human and mouse plasma, EGCG concentration may reach 1.3
μM and 13.6 μM, respectively (Van Amelsvoort et al., 2001; Lambert et al., 2003). No data
are available for tissue concentrations of various catechins in humans after tea consumption,
but in mice, the concentrations of EGCG may reach 3.56 nMol/g in liver and 2.4 nMol/g in
intestine (Lambert et al., 2003), which suggests that FXR should be activated by EGCG in
vivo.
Furthermore, we found that EGCG acts as a unique modulator of FXR. EGCG alone is a
FXR activator. However, in the presence of other potent agonists, such as GW4064 or
CDCA, EGCG acts as an antagonist of FXR activation. EGCG dose-dependently inhibited
GW4064-mediated coactivator recruitment to FXR (Figure 4A). In addition, EGCG
inhibited FXR agonist-mediated induction of FXR target genes in HepG2 cells (Figure 4B).
Guggulsterone, which is extracted from the Commiphora mukul tree, has been reported to
function as a FXR partial agonist (Cui et al., 2003; Deng et al., 2007). Similar to EGCG,
guggulsterone alone activated FXR but suppressed coactivator recruitment to FXR induced
by other FXR agonists. However, while EGCG inhibited the transactivity of other FXR
agonists, guggulsterone paradoxically enhanced other agonists’ action in FXR target gene
induction in vitro (Cui et al., 2003). This data suggests that EGCG and guggulsterone
represent two different classes of FXR modulators.
Our study also identified EGCG as a tissue- and gene-specific FXR modulator in vivo.
EGCG only activated intestinal FXR without affecting the expression of FXR target genes in
the liver. In addition, EGCG induced expression of some, but not all, FXR target genes in
the intestine including both Shp and Fgf15, but not Ibabp. The reason that EGCG tissue-
specifically activates FXR may be due to rapid metabolism and elimination of EGCG from
the liver or interaction with endogenous FXR ligands. Moreover, the low bioavailability and
poor stability of EGCG may also contribute to the tissue-specific activation of FXR. Studies
have shown that following intravenous administration, EGCG is rapidly conjugated and
eliminated in the liver (Lambert et al., 2003) with glucuronidation as the most abundant
pathway in EGCG metabolism (Lambert et al., 2003; Lu et al., 2003). We found that a high
concentration of EGCG (100 μM) suppresses FXR target genes in the presence of a potent
FXR agonist in vitro (Figure 5). However, it is hard to reach this concentration in vivo due to
fast metabolism of EGCG. Furthermore, EGCG can activate intestinal FXR by P.O.
administration of 100 mg/kg in mice, but this concentration is too high to achieve in humans
by drinking green tea only. A combination of consuming green tea in the diet with taking
EGCG supplements is a likely approach to increase the dose of EGCG in humans.
In the current study, our results suggest that EGCG functions as a unique FXR modulator.
However, EGCG showed inhibitory effects on FXR transactivation in the presence of potent
FXR agonists, CDCA and GW4064 (Figure 4B). Thus it is possible that in liver, EGCG
functions as a FXR antagonist in the presence of high concentrations of bile acids. In
addition, it may function as a FXR agonist in intestine, which contains lower levels of bile
acids.
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Tea and tea catechins are well-known for their beneficial effects in improving digestion and
chemoprevention of cancers, especially in the oral cavity and intestinal tract where higher
EGCG concentrations are achieved (Deng et al., 2007; Yang et al., 2007). The mechanisms
of cancer prevention of EGCG may be associated with decreased cell proliferation and
increased apoptosis, specifically with decreased nuclear levels of β-catenin (Yang et al.,
2009). FXR deficiency in mice leads to increased colon cancer incidence (Maran et al.,
2009), and the expression and function of FXR is markedly reduced in human colorectal
cancers (De Gottardi et al., 2004). FXR may modulate inflammatory responses, cell
proliferation and apoptosis in liver, intestine and breast (Smith et al.; Kim et al., 2007b;
Modica et al., 2008; Journe et al., 2009; Maran et al., 2009). Therefore, maintaining FXR
function in intestine may help prevent or reduce intestinal tumorigenesis. Although not yet
tested, FXR activation may represent a mechanism responsible for the effect of tea in
reducing gastrointestinal tract cancer risk.
In summary, tea catechins, especially EGCG, are FXR selective modulators. EGCG is the
major polyphenol in green tea, and it functions as a unique modulator of FXR. EGCG
moderately activates FXR by itself, but inhibits transactivation of FXR by other agonists.
Oral administration of low concentrations of EGCG activates FXR to induce a subset of
FXR target genes in the small intestine but does not induce FXR target gene expression in
the liver. Activation of FXR may represent a novel mechanism of EGCG in improving
intestinal health.
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FXR farnesoid X receptor
Ibabp ileum bile acid binding protein
I.P intraperitoneally
OSTα organic solute transporter α
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Epigallocatechin-3-gallate (EGCG) is a unique farnesoid X receptor (FXR)
modulator.
EGCG activates FXR by itself, but inhibits FXR transactivation by other agonists.
Low concentration of EGCG activates FXR in mouse intestine but not liver.
EGCG activates FXR to induce a subset of FXR target genes in mouse intestine.
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Figure 1. Chemical structure of EGCG, EGC, and ECG, in comparison to a known FXR agonist,
GW4064
Chemical structure of tea catechins, (−)-epigallocatechins-3-gallate (EGCG), (−)-
epigallocatechin (EGC), (−)-epicatechin-3-gallate (ECG), and GW4064.
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Figure 2. Screen of tea preparations for modulation of FXR activity, determined by luciferase
assay
HepG2 cells were transfected with various plasmids indicated in the Methods. Five hours
after transfection, cells were treated for 36 hours with different tea compound mixtures at
two concentrations, 10 and 100 μM. The two mixtures A007 (ECG + EGC) and A009 (EGC
+ EGCG) contain equal molar concentrations of individual tea catechins. GW4064 at 1 μM
was used as a positive control, and 0.1% DMSO was used as a negative control. The cells
were lysed, and luciferase activities were determined to indicate FXR activation. An asterisk
represents P < 0.05 between 10 μM treatment and DMSO group; a pound sign represents P <
0.05 between 100 μM treatment and DMSO group.
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Figure 3. Dose response of catechins in activation of FXR, determined by luciferase assay
HepG2 cells were transfected with various plasmids indicated in the Methods. Five hours
after transfection, cells were treated with 1μM GW4064 (positive control), 0.1% DMSO
(negative control), or increasing concentrations of catechins, from 0.01 μM to 100 μM, for
36 hours before measuring luciferase activity. A, Dose-dependent activation of FXR by
ECG, EGC, or EGCG. An asterisk indicates P < 0.05 versus 0.01 μM treatment group. B,
The EC50 of EGCG in activating FXR is 2.99 μM.
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Figure 4. The effect of EGCG on both basal and GW4064-mediated coactivator recruitment to
and transactivation of FXR
A, The fluorescence resonance transfer (FRET) hFXR coactivator recruitment assays were
performed as described in the Methods. The x axis represents the log of increasing
concentrations of EGCG alone, GW4064, or EGCG combined with 500 nM of GW4064.
The y axis represents relative FXR coactivator recruitment activity. FRET ratios were
normalized so 100% activation and 0% activation represent the activity of GW4064 at 100
μM and 0 μM, respectively. The results showed that (1) EGCG alone did not lead to
coactivator recruitment, and (2) EGCG inhibited GW4064-mediated recruitment of
coactivator to FXR in a dose responsive manner. The IC50 of EGCG is ~1 μM.
B, Effects of EGCG on other agonists (GW4064 and CDCA) transactivation of FXR as
determined by luciferase assay. HepG2 cells were transfected with various plasmids
indicated in the Methods. Five hours after transfection, cells were treated with 0.1% DMSO
as a negative control or with increasing concentrations of EGCG, from 0 μM to 100 μM,
combined with 500 nM GW4064 or 100 μM CDCA for 36 hours before measuring
luciferase activity. An asterisk indicates P < 0.05 between the combined treatment and the
no EGCG treatment group. Double asterisks indicate P < 0.01 between the combined
treatment and the no EGCG treatment group.
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Figure 5. Effects of EGCG on FXR target gene induction by GW4064 and CDCA in HepG2 cells
HepG2 cells were treated with 500 nM GW4064 or 100 μM CDCA for 24 hours in the
absence or presence of increasing concentrations of EGCG (1, 10 and 100 μM). The mRNA
levels of FXR, SHP, OSTα, OSTβ and BSEP were determined by Q-PCR with n=3 per
group. The results for each gene were normalized to vehicle control. An asterisk represents
P < 0.05 between the treatment and no EGCG treatment group. Double asterisks indicate P <
0.01 between the combined treatment and no EGCG treatment group.
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Figure 6. Mouse serum alanine aminotransferase (ALT) levels with EGCG treatment
Serum levels of ALT were determined after WT and FXR-KO mice were treated twice in
one day with EGCG at 100 mg/kg for P.O. or at 25 mg/kg for I.P.. Data are expressed as
mean ± SD, n = 5 mice per group.
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Figure 7. Induction of FXR target genes in ileum of WT and FXR-KO mice following acute
EGCG treatment
WT and FXR-KO mice were treated twice in one day with EGCG at 100 mg/kg for P.O. or
at 25 mg/kg for I.P. The control groups were treated with vehicle. Intestinal mRNA levels of
Fxr, Shp, Ibabp, and Fgf15 were determined by Q-PCR (n = 5 mice per group). An asterisk
indicates P < 0.05 between the treatment and vehicle control group. Double asterisks
indicate P < 0.01 between the treatment and vehicle control group.
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